FDA Grants Priority Review to Rituxan sBLA for Non-Hodgkin's Lymphoma

Drug Industry Daily
KEYWORDS FDA
A A

The FDA has granted priority review to Genentech and Biogen Idec’s supplemental biologics license application (sBLA) for Rituxan as a front-line treatment for non-Hodgkin’s lymphoma.

To View This Article:

Login

Subscribe To Drug Industry Daily